Reify Health

Software platform for clinical trial enrollment

Boston, Massachusetts, United States

About Reify Health

Reify Health focuses on improving the clinical trial process, specifically in the area of patient recruitment and enrollment. Its main product, StudyTeam, is a software platform that assists research sponsors, such as pharmaceutical companies and biotech firms, in managing and speeding up patient enrollment for clinical trials. The platform provides real-time access to pre-screening and enrollment data, enabling sponsors to adjust their strategies and timelines proactively. This feature enhances visibility and control, making the enrollment process more predictable and efficient. Unlike its competitors, Reify Health operates on a subscription-based software-as-a-service (SaaS) model, which allows clients to pay a recurring fee for access to the StudyTeam software. The goal of Reify Health is to reduce the time and costs associated with patient enrollment, ultimately improving the efficiency and success rates of clinical trials.

Boston, MassachusettsHeadquarters
2012Year Founded
$464.5MTotal Funding
SERIES_DCompany Stage
Enterprise Software, Biotechnology, HealthcareIndustries
51-200Employees

Benefits

Comprehensive health and wellness
Generous parental leave
Flexible paid time off
401(k) company match

Risks

Emerging competitors threaten Reify Health's market share with innovative features.
Key personnel departures may disrupt projects and innovation.
Economic downturns could reduce clinical trial budgets, impacting service demand.

Differentiation

Reify Health's StudyTeam accelerates clinical trial enrollment, reducing time and costs.
The platform offers real-time data access, enhancing strategy adjustments for trial sponsors.
Reify Health focuses on patient recruitment, a critical bottleneck in clinical trials.

Upsides

Increased adoption of decentralized trials enhances patient recruitment and retention.
AI integration in trial management improves data analysis and patient matching.
Focus on diversity in trials aligns with regulatory and sponsor priorities.

Funding